ArticleDiabetologia2004
Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data.
Article in Diabetologia, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2018 · on this mapPooled it
- Alpha-glucosidase inhibitors for type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2005Pooled it
- MARCH2: comparative assessment of therapeutic effects of acarbose and metformin in newly diagnosed type 2 diabetes patients.PloS one · 2014 · on this mapTrial
- Trial
- Beyond Diabetes: Continuous Glucose Monitoring as a Candidate Precision Tool for Cardiovascular Prevention and Healthy Longevity-A Hypothesis-Generating Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Characterizing epidemiology of prediabetes, diabetes, and hypertension in Qataris: A cross-sectional study.PloS one · 2021Article
- Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetes.Current cardiology reports · 2013Review
- Counterpoint: postprandial glucose levels are not a clinically important treatment target.Diabetes care · 2010Article
- Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes.Diabetes care · 2009Review
- d-Psicose Inhibits Intestinal alpha-Glucosidase and Suppresses the Glycemic Response after Ingestion of Carbohydrates in Rats.Journal of clinical biochemistry and nutrition · 2009Article
- Review
- Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes.Vascular health and risk management · 2008Review
- [Pre-diabetes in primary care: diagnosis... and treatment?].Atencion primaria · 2006Review
- Diabetes and ethnic minorities.Postgraduate medical journal · 2005Review
- Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCardiovascular morbidity and mortality is a major and still unresolved threat to patients with reduced glucose tolerance and Type 2 diabetes mellitus. In epidemiological studies, in non-diabetic subjects, post-prandial glycaemia is positively associated with the risk of diabetes, hypertension and cardiovascular events. If this epidemiological association is causal, Acarbose, which reduces post-prandial blood glucose concentrations, should result in a decrease in the risk of these events. The STOP-NIDDM trial investigated whether Acarbose reduces the risk of diabetes, hypertension and cardiovascular events. Consequently, the validity of the results of this trial is of major importance for future treatment in non-diabetic and diabetic patients.
methodsWe searched various databases and the Internet for publications of the design and the results of the STOP-NIDDM trial. A systematic review of these publications was done with respect to information about potential sources of bias and contradictory information in the articles.
resultsWe found several serious flaws in the STOP-NIDDM study, especially selection bias, inadequate blinding, bias in data analysis and reporting, and potential sponsoring bias.
conclusionsThe validity of the results of the STOP-NIDDM trial is seriously flawed. The clinical benefit of Acarbose and of the reduction of post-prandial glycaemia is unproven.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.